Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer

摘要

Lung cancer is one of the leading causes of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of lung cancers, and about 70% are diagnosed as advanced disease (1). Until recently, systemic chemotherapy has been the standard treatment for patients with metastatic NSCLC with limited efficacy; however, identification of driver mutations, such as epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) rearrangements, and the development of tyrosine kinase inhibitors for each genetic alteration markedly changed current clinical practice (2,3).